Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) EPS (Basic): HK$ (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) EPS (Basic)?

Alebund Pharmaceuticals (Jiangsu) HKSE:09637 -2.87% 5 EPS (Basic) is HK$ as of Dec. 2025. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review.

Alebund Pharmaceuticals (Jiangsu)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-2.44. Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025.

Alebund Pharmaceuticals (Jiangsu)'s EPS (Diluted) for the six months ended in Dec. 2025 was HK$-2.44. Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025.

Alebund Pharmaceuticals (Jiangsu)'s EPS without NRI for the six months ended in Dec. 2025 was HK$-2.44. Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Alebund Pharmaceuticals (Jiangsu)  (HKSE:09637) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alebund Pharmaceuticals (Jiangsu) EPS (Basic) Related Terms

Alebund Pharmaceuticals (Jiangsu) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Alebund Pharmaceuticals (Jiangsu)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alebund Pharmaceuticals (Jiangsu) EPS (Basic) Chart

Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend Dec24 Dec25
EPS (Basic)
-1.02 -2.44

Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24 Dec25
EPS (Basic) -1.02 -2.44
HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Alebund Pharmaceuticals (Jiangsu)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-828.586-0)/339.852
=-2.44

Alebund Pharmaceuticals (Jiangsu)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-828.586-0)/339.852
=-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$ mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a EPS (Basic) of HK$ as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s EPS (Basic) too high?
Alebund Pharmaceuticals (Jiangsu)'s current EPS (Basic) is HK$. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s EPS (Basic) compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s EPS (Basic) of HK$ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current EPS (Basic) is HK$. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current EPS (Basic) of HK$. The current EPS (Basic) is HK$. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current EPS (Basic) is HK$ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price